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Prognosis and survival of patients with hepatocellular carcinoma (HCC) is still very poor, and no therapies are currently available to
inhibit tumour growth and metastases. Recently, we reported that the expression of an extracellular matrix component (ECM),
namely Laminin-5 (Ln-5), is directly related to poor prognosis in HCC patients. The aim of our study is to investigate the preclinical
effect of gefitinib in an in vitro HCC model. We found that the IC50 of gefitinib in HCC cells ranged from 0.7 to 10.0mM, whereas Ln-5
inhibited the activity of gefitinib in a dose-dependent manner. Complete inhibition of phosphorylated (p)-EGFR (epidermal growth
factor receptor) was obtained within 6h exposure to gefitinib and complete restoration of the receptor status was obtained after
24h. A downstream effect yields a decrease in p-Akt and p-Erk 1/2. The addition of exogenous Ln-5 has no effect on p-EGFR,
whereas it restores p-Erk 1/2 and p-Akt. Consistently, Ln-5 induces recovery of HCC cells from Gefitinib-induced apoptosis. In
conclusion, gefitinib inhibits HCC cell growth and we report for the first time that Ln-5, but not other ECM molecules, reduces the
ability of gefitinib to inhibit cell growth via Akt. As patients with HCC have different Ln-5 expression levels, these results may help to
better understand which patients might benefit from gefitinib treatment.
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Hepatocellular carcinoma (HCC) is the fifth most frequent
malignancy in the world and the third cause of tumour-related
death. Furthermore, it is estimated that in coming years, the
occurrence of HCC will increase in Western countries, due to
hepatitis C virus diffusion (Bruix and Llovet, 2002). In HCC
patients, prognosis and survival are still unsatisfactory mainly
because of tumour recurrence and metastatic diffusion (Giannelli
et al, 2002b).
The molecular mechanisms responsible for HCC spread are not
yet known; however, we have recently reported that the expression
of an extracellular matrix (ECM) component, namely Laminin-5
(Ln-5), is strongly associated in vivo with a more aggressive and
invasive phenotype of HCC and with a worse prognosis (Giannelli
et al, 2003). Ln-5, a major component of the basement membrane,
plays a crucial role for epithelial cells so that its genetic absence is
responsible for lethal disease (Meneguzzi et al, 1992). It promotes a
number of different biological functions including adhesion,
migration and scattering and it has been reported to play a role
in cancer metastasis (Miyazaki et al, 1993; Baker et al, 1996; Xia
et al, 1996). Integrins a3b1 and a6b4, the two main receptors for
Ln-5, are highly expressed in epithelial cancer cells (reviewed in
Giannelli et al, 2002a).
So far, no drugs are available to inhibit tumour growth and/or
metastatic spread of HCC and current therapies are restricted to
surgery, ethanol injection, radiotherapy and chemoembolisation.
Recently, gefitinib (‘Iressa’), an orally active epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor that blocks signal
pathways implicated in cancer growth and metastasis, has been
successfully used in lung and colon cancer (Douglass, 2003;
Haringhuizen et al, 2004; Johnson et al, 2004), where it could
represent an alternative monotherapy for patients with advanced
tumours (Herbst, 2003). In two large-scale Phase II trials,
approximately 50% of previously treated patients with NSCLC
had either an objective response or disease stabilisation following
treatment with gefitinib 250mgday
 1 (Fukuoka et al, 2003; Kris
et al, 2003). Furthermore, it has been reported to reduce tumour
growth and metastasis occurrence in a xenograft HCC animal
model (Matsuo et al, 2003), and in the USA a Phase II trial treating
patients with HCC with gefitinib is currently underway.
The goal of our study is to investigate the potential therapeutic
effect of, and the potential resistance to, gefitinib in an in vitro
HCC model; in particular, we analysed gefitinib’s ability to inhibit
cell growth, and whether the Ln-5 ECM molecule reduced its
efficacy.
MATERIALS AND METHODS
Gefitinib activity was tested on four different human HCC cell
lines, in the absence and presence of Ln-5.
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sReagents
Gefitinib was kindly provided by AstraZeneca Pharmaceuticals,
UK. Stock solutions were prepared at 20mM in dimethyl
sulphoxide (DMSO) and stored in aliquots at  201C. Purified
Ln-5 was prepared as previously described (Koshikawa et al, 2000).
Working dilutions were made in culture medium supplemented
with 10% fetal bovine serum, 2mM glutamine, 50000UL
 1
penicillin and 80mM streptomycin.
Laminin-1 (Ln-1) and Collagen IV (Coll IV) were purchased
from Sigma Chemical Company (St Louis, MI, USA), Coll I from
BD Biosciences (Bedford, MA, USA), Fibronectin (Fn) from
Calbiochem (La Jolla, CA, USA), Fibrinogen (Fg) and Vitronectin
(Vn) were gifted by Dr Felding-Habermann (TSRI, La Jolla, CA,
USA) (Felding-Habermann et al, 2002).
Cell culture
Alexander, HepG2, HLF and Sk-Hep1 human HCC cell lines were
routinely cultured in RPMI or DMEM medium supplemented with
10% fetal bovine serum (2mM glutamine, 50000UL
 1 penicillin
and 80mM streptomycin) in a humidified incubator at 371C with an
atmosphere containing 5% CO2. Cells were trypsinised once a week
with trypsin/ethylenediaminetetraacetic acid (EDTA) (0.25%/
0.02%) and the medium was changed twice a week (Giannelli
et al, 2001).
Antibodies
Antiphosphotyrosine polyclonal antibody PY99 was purchased
from Santa Cruz Biotechnology, USA; anti-EGFR monoclonal
antibody from Becton-Dickinson (San Diego, CA, USA) and the
following monoclonal antibodies were from Cell Signaling (USA):
anti-Akt, anti-phosphoAKT, anti-ERK1/2 and anti-phospho-ERK1/
2. Mouse and rabbit horseradish peroxidase (Amersham Pharma-
cia Biotech, Upsala, Sweden) were used as secondary antibodies.
Anti-a3 and anti-a6 integrin blocking antibodies were purchased
from Gibco (Gaithersburg, MA, USA) and from Pharmingen (San
Diego, CA, USA).
Cytotoxicity assay
Gefitinib determination of IC50 was performed using the 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromide (MTT) as-
say. Briefly, 7500 cells in a volume of 200ml were plated in each
well on a 96-well plate. After 24h, cells were challenged for 3 days
with gefitinib at the following concentrations: 0.01, 0.1, 0.5, 1.0, 5.0,
10.0 and 50.0mM. Each experiment was reproduced in seven
different wells, and each experiment repeated at least three times.
Results were expressed as a dose–response curve with a plot of the
fraction of unaffected (surviving) cells vs the drug concentration.
IC50 was defined as the drug concentration yielding 50% of affected
(nonsurviving) cells compared with untreated controls. In some
experiments, Ln-1, Ln-5, Coll IV, Coll I, Fg, Fn and Vn (1mgml
 1)
were added to cells in the presence of gefitinib IC50 and the cell
growth inhibition was measured by the MTT assay. Ln-5 was also
tested at different concentrations (ranging from 0.3 up to
3.0mgml
 1).
Anti-a3 and anti-a6 integrin-blocking antibodies (30mgml
 1)
were added together with Ln-5 in the presence of gefitinib IC50 and
the cell growth inhibition was measured by the MTT assay.
Western blot analysis
Protein samples were extracted from gefitinib (IC50)- and/or Ln-5
(1mgml
 1)-treated cells (3 10
6 cells) after homogenisation in
RIPA buffer (0.5 M NaCl, 1% Triton X-100, 0.5% NP40, 1%
deoxycolic acid, 3.5mM sodium dodecyl sulphate (SDS), 8.3mM
Tris HCl pH 7.4, 1.6mM Tris base) and treated with a 20% protease
inhibitor cocktail (Sigma, MO, USA). Protein concentration was
determined by the Bradford method, samples were normalised for
protein concentration (25–50mg), and electrophorised on 10–
12.5% SDS–PAGE. The signal was detected by the chemolumines-
cence assay (ECL-Plus, Amersham Life Science, UK) and the
expression level was calculated by densitometric analysis using
Multi-Analyst software (Biorad, Hercules, CA, USA), using b-actin
expression as internal standard.
Immunoprecipitation analysis
HCC cells (3 10
6) were treated with gefitinib (IC50) and/or Ln-5
(1mgml
 1) for 24h. Cells were lysed in RIPA-IP buffer (140mM
NaCl, 20mM Tris/HCl, 10mM EDTA pH 8, 10% glycerol, 1% NP40,
1m M Na-deoxycolic acid, 1mM phenylmethylsulphonyl fluoride
(PMSF)), passed through a 22-gauge syringe and cleared by
centrifugation at 10000g at 41C for 10min. Proteins were
immunoprecipitated by incubating 0.1–0.3mg of total cell lysate
with 0.2mg of antiphosphotyrosine antibody or anti-EGFR anti-
body for 1h at 41C. In all, 2–5ml of protein A/G agarose (Santa
Cruz Biotechnology, USA) were incubated overnight at 41C. Cell
suspension was centrifuged at 2600r.p.m. and the pellet was
washed three times with phosphate-buffered saline (PBS) and then
resuspended in 10ml of Laemmli buffer. Each sample was
separated on 10% acrylamide gel and Western blot was performed
as described above.
Apoptosis analysis
Apoptosis detection was performed by Annexin V-FITC staining
assays (Biovision, Palo Alto, CA, USA). In accordance with the
manufacturer’s instructions, HCC cells (5 10
5) were incubated
with Annexin V at room temperature for 10min. Apoptotic cells
were detected by FACS analysis (Becton-Dickinson, NJ, USA) and
quantified using cellquest software (Becton-Dickinson).
Apoptosis detection was further investigated by the Cell Death
ELISA
PLUS kit (Roche Molecular Biochemicals, Milan, Italy). The
test is based on the detection of mono- and oligonucleosomes in
the cytoplasmic fraction of cell lysates by biotinylated antihistone-
coupled antibodies, and their enrichment in the cytoplasm is
calculated as the absorbance of sample cells/absorbance of control
cells. The enrichment factor was used as a parameter of apoptosis
and shown on the Y-axis as mean7standard deviation (s.d.).
Experiments were performed according to the manufacturer’s
instructions.
Statistical analysis
Results are expressed as the mean7s.d. and the statistical
significance of the Ln-5-dependent reduction of gefitinib activity
was determined by Student’s t-test with a 95% confidence interval.
RESULTS
All the experiments of gefitinib-induced cytotoxicity were
evaluated after 3 days of continuous exposure, therefore the use
of FCS in the in vitro culture system was required to ensure cell
vitality; this is consistent with other studies (Magne et al, 2003;
Tortora et al, 2003; Xu et al, 2003b). Furthermore, we have
previously shown the stability of the drug in the presence of serum
in the HPLC system (Porcelli et al, 2004).
Epidermal growth factor receptor and downstream
effectors expression on HCC cell lines
As shown in Figure 1, the expression level of EGFR is higher in
HLF and Sk-Hep1 cells than in Alexander and HepG2 cells, while
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sthe p-EGFR form is more evident in Alexander and HLF cells than
in HepG2 and Sk-Hep1 cells. On the contrary, no differences were
observed between HCC cell lines in terms of Erk 1/2, p- Erk 1/2,
Akt and p-Akt expression.
Gefitinib inhibits HCC cell lines growth
To provide preclinical evidence of the effectiveness of gefitinib in
HCC, we tested the sensitivity of four distinct human HCC cell
lines to different drug concentrations after 3 days incubation,
consistent with a long period of drug utilisation in clinical trials.
All the cell lines were investigated under the same experimental
conditions to limit biological variability. As reported in Table 1,
HCC cell lines showed similar gefitinib IC50 values. Experiments
were repeated at least three times, and the mean and standard
deviation refer to all the experiments.
Extracellular matrix proteins modulate gefitinib
effectiveness
To investigate whether ECM proteins such as Ln-1, Ln-5, Coll I,
Coll IV, Fg, Fn and Vn can interfere with gefitinib’s ability to
inhibit cell growth of HCC cell lines, we added exogenous matrices
(1mgml
 1) to the cells in the presence of gefitinib IC50. As shown
in Table 2, gefitinib-dependent cell cytotoxicity (50%) was
dramatically reduced by the presence of Ln-5, with a consequent
significant increase of cell survival (Po0.001), whereas no effect
was observed with any of the other ECM proteins used. However,
this Ln-5 activity was completely inhibited by anti-a3 but not by
anti-a6 integrin-blocking antibodies in HLF cells, and was
completely inhibited by anti-a6 in Alexander cells. These results
are consistent with our previous work reporting a strong
expression of a3 integrin in HLF, while Alexander cells were a3
integrin negative but intensely a6 positive (Giannelli et al, 2001).
To better characterise the interaction of Ln-5 with gefitinib
treatment, HCC cell lines were incubated with gefitinib (IC50)i n
the presence of different Ln-5 concentrations. As shown in Figure 2,
gefitinib’s ability to inhibit cell growth was Ln-5 dose-dependent;
in particular, complete inhibition of the drug-induced effect was
obtained with 3mgml
 1 of Ln-5, while no changes were observed
with 0.03mgml
 1 of Ln-5.
In conclusion, gefitinib inhibited growth of HCC cell lines,
whereas Ln-5 inhibited the gefitinib-induced activity in a dose-
dependent manner.
Cellular response to gefitinib and/or Ln-5
Molecular targets To study the molecular mechanisms respon-
sible for the interaction between gefitinib and Ln-5, we analysed
the modulation of drug-specific cell targets such as EGFR, as well
Akt
EGFR
Erk1/2
p-Erk1/2
p-Akt
-Actin
p-EGFR
Alexander
HLF
HepG2
Sk-Hep1
Alexander
HLF
HepG2
Sk-Hep1 A
B
Figure 1 EGFR and downstream effectors expression on HCC cell lines.
EGFR, Erk 1/2, p-Erk 1/2, Akt, p-Akt expression in HLF, Alexander, HepG2
and Sk-Hep1 cellular extracts were analysed by Western blotting (A).
Phosphorylated-EGFR was determined by immunoprecipitation followed
by Western blotting (B).
Table 1 Gefitinib IC50 in HCC cell lines after 3 days incubation
Cell lines Gefitinib (lM)
Alexander 0.6770.22
HepG2 4.7370.42
HLF 4.0470.54
Sk-Hep1 10.171.76
Table 2 Percentage of survived HCC cells treated with Gefitinib (IC50)
in the presence of ECM proteins
Sk-Hep1 Alexander HLF HepG2
Gefitinib 5073.7 5071.3 5078.4 50710
Gefitinib+LN-5 7876.9 84711.0 8175.8 81709
Gefitinib+Coll I 6276.9 5577.9 5679.5 5876.8
Gefitinib+Coll IV 6377.0 5772.3 5879.2 6175.9
Gefitinib+Fib 6176.6 5574.8 5776.2 5977.9
Gefitinib+FN 6275.4 5771.8 5578.3 5976.9
Gefitinib+LN-1 5779.7 5472.7 5975.0 5574.7
Gefitinib+VN 5977.5 5871.0 5675.6 5776.8
Each experiment was carried out in triplicate.
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Figure 2 Ln-5 modulation of Gefitinib IC50 effectiveness on HCC cells is
dose-dependent. Ln-5 inhibits Gefitinib IC50 effectiveness at 3mgml
 1,
while it is not effective at 0.03mgml
 1 on HLF (~), Alexander (’), Sk-
Hep1 (m) and HepG2 (X) cells.
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sas the main steps of its signal transduction pathways, including
Erk1/2 and Akt.
Neither gefitinib nor Ln-5 affected EGFR, Akt and Erk1/2
expression compared to controls using b-actin expression as
internal standard.
On the contrary, the p-EGFR form was completely inhibited
after 6h of drug treatment (IC50) and recovered after 1 day, while
no effect was observed after the addition of Ln-5 (Figure 3).
Consistently, p-Erk 1/2 and p-Akt were both inhibited, with some
differences between Alexander and HLF cells. After a short time of
drug exposure (6h), gefitinib inhibited both effectors more
efficiently in Alexander than in HLF cells (Figure 4). No effect of
Ln-5 alone was observed on either effector, whereas Ln-5-treated
cells showed a reduced gefitinib inhibition of p-Akt from 15 to 25%
(P40.05) and from 25 to 35% (P40.05) in Alexander and HLF
cells, respectively, and of p-Erk1/2 from 2 to 20% (P¼0.02) and
from 60 to 80% (P¼0.03) in Alexander and HLF cells, respectively.
After 24h of gefitinib and/or Ln-5 exposure, no differences
between Alexander and HLF cells were evident. As shown in
Figure 5, p-Erk1/2 returned to baseline even in the absence of Ln-5,
whereas p-Akt inhibition decreased, in the presence of Ln-5, from
70 to 30% (Po0.02) and from 60 to 20% (Po0.02) in Alexander
and HLF cells, respectively. In conclusion, the recover of the
effector forms in the presence of Ln-5 is time-dependent.
Apoptosis induction
Apoptotic cells were quantified using Annexin V and cytoplasmic
histone-associated-DNA fragmentation assays. After three days of
gefitinib exposure, there were 7 and 5% Annexin V positive cells
and the mono- and oligonucleosomes enrichment factor was
4.370.4 and 3.870.2, in Alexander and HLF cells, respectively.
Consistently with the Ln-5 effect on gefitinib-dependent p-Akt
inhibition, in Ln-5-treated cells exposed to gefitinib treatment,
Annexin-positive cells were less than 1% while the enrichment
factor was less than 1.870.2 in both cell lines.
DISCUSSION
Prognosis and survival of HCC patients is still poor. Nevertheless,
no drug treatment is currently available to block or reduce cancer
growth and/or tumour metastasis. This is mainly because the
molecular mechanisms regulating the aggressive and malignant
phenotype of HCC are still unknown. However, it has been
reported that the expression of Ln-5 is strongly correlated with a
worse prognosis in HCC patients (Giannelli et al, 2003). No
therapies are so far available to inhibit or reduce HCC growth and
invasion.
Gefitinib, a target-oriented drug that inhibits EGFR tyrosine
kinase, has been successfully used to reduce lung and colon cancer
growth and metastasis (Sirotnak, 2003; Xu et al, 2003a,b; Azzariti
et al, 2004). Recently, it has been reported that gefitinib reduces
tumour growth and metastatic spread of HCC in a mouse
experimental model (Matsuo et al, 2003). Furthermore, a Phase
Alexander  p-EGFR
0 1h 6h 24h
HLF            p-EGFR
Gefitinib IC50 + Ln−5 (1 g ml
−1)
30 min 0 1h 6h 24h 30 min
Gefitinib IC50
Figure 3 Time course of Gefitinib-dependent p-EGFR inhibition in HCC
cells in the presence and absence of Ln-5. p-EGFR is completely inhibited
after 6h and completely recovers after 24h both in the presence and
absence of Ln-5.
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Figure 4 Ln-5 modulation of 6h Gefitinib activity on molecular targets. Ln-5 (1mgml
 1) does not reverse Gefitinib (IC50) effectiveness on p-EGFR, but
partially restores p-Akt and p-Erk 1/2 on Alexander and HLF cells.
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sII trial with gefitinib in patients with HCC is currently ongoing in
the USA; however, no data are yet available on HCC cell sensitivity.
In this study, we investigated the effectiveness of an in vitro
HCC model to gefitinib. Our results show that gefitinib is effective
on HCC growth, but its activity is inhibited by Ln-5. We base this
conclusion on the following data: (1) gefitinib inhibits HCC cell
growth; (2) Ln-5 antagonises gefitinib growth inhibition in a dose-
dependent manner; (3) gefitinib induces persistent dephosphor-
ylation of Akt, while with Ln-5 the p-Akt form recovers; (4)
gefitinib-induced late apoptosis is reversed by Ln-5.
In other cancers, such as colon and lung carcinoma, the
downstream effect of inhibiting EGFR phosphorylation involves
both the Akt and Erk1/2 pathways (Azzariti et al, 2004), but unlike
other cancer systems, in the HCC model, there is transient
inhibition of the proliferation pathway (p-Erk1/2), while there is
persistence of the survival pathway (p-Akt), inducing cell growth
inhibition and apoptosis.
Moreover, we reported that the effect of gefitinib on its
downstream effectors, p-Akt and p-Erk1/2, is time-dependently
reversed by Ln-5, which is expressed de novo in HCC but not in
peritumoral or normal tissues (Giannelli et al, 2003), whereas no
effects are observed with other ECM molecules such as Ln-1, Coll I,
Coll IV, Fn, Fg and Vn. To our knowledge, this is the first evidence
of an ECM molecule inhibiting the effectiveness of gefitinib,
although protection from apoptosis by ECM proteins has been
reported in small-cell lung carcinoma (Sethi et al, 1999) (Table 2).
Thus, we could hypothesise that Ln-5 expression could be a
predictive factor for gefitinib response in HCC. Moreover, since
Ln-5 is widely distributed in human tissues including lung and
colon, our data could contribute to explain differential respon-
siveness to gefitinib (Haringhuizen et al, 2004). The mechanisms
responsible for the recovery of the p-Akt form are still unknown
and require further investigation; however, we can role out the
possibility that Ln-5 physically interacts with gefitinib since p-
EGFR is inhibited even in the presence of Ln-5. Furthermore, in
our model, it is very likely that both the a6b4 and a3b1 integrins
are involved in the Ln-5 signal pathway since both anti-a3- and
anti-a6-blocking antibodies inhibit Ln-5-mediated survival in
cytotoxicity experiments. Thus, consistently with our previous
work (Giannelli et al, 2001), in the HCC model, it is possible that
either a3b1o ra6b4 are implicated in signal transduction, mainly
depending on which receptor is predominantly expressed. There-
fore, these data could contribute to explain the discrepancy in the
literature between the involvement of a3b1 and a6b4 in cancer
aggressiveness.
In conclusion, gefitinib inhibited cell growth in all the human
HCC cell lines studied. Furthermore, for the first time, we have
shown that a widely distributed ECM molecule, namely Ln-5,
inhibits gefitinib’s ability to inhibit cell growth. For HCC patients,
differential expression levels of Ln-5 may help to understand
which patients might benefit from gefitinib treatment.
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